ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Monday following the company's announcement of significant revenue growth.

Benzinga • Feb 23, 2026

Why ImmunityBio Stock Is Soaring Again Today

ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock.

The Motley Fool • Feb 23, 2026

Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%

On Feb. 23, 2026, investors weighed ANKTIVA's explosive revenue ramp against ImmunityBio's deep losses and ambitious global expansion.

The Motley Fool • Feb 23, 2026

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product revenue for ANKTIVA, representing an approximately 700% increase year-over-year. The Company also reported a 750% increase in unit sales volume and a 20% quarter-over-quarter increase in net product revenue, demonstrating sustained commercial momentum. In parallel.

Business Wire • Feb 23, 2026

ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.15 per share a year ago.

Zacks Investment Research • Feb 23, 2026

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at "Cancer 2035: A Roadmap for the Future," a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 2026. T.

Business Wire • Feb 23, 2026

Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More

The Undercovered Dozen series spotlights 12 less-covered stocks highlighted in recent Seeking Alpha articles. This week's edition covers articles published between Feb. 13 and Feb. 19, offering fresh investment ideas. The series aims to inspire discussion and help investors discover overlooked opportunities in the market.

Seeking Alpha • Feb 23, 2026

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region. Under the agreement, Biopharma and Cigalah Healthcare will support the commercialization and distribution.

Business Wire • Feb 20, 2026

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

ImmunityBio Inc (NASDAQ: IBRX) stock is maintaining a confirmed Golden Cross, with the stock now trading roughly 170% above its 200-day moving average — a measurable signal of sustained long-term trend strength.

Benzinga • Feb 19, 2026

ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up

IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its global footprint to 33 countries.

Zacks Investment Research • Feb 19, 2026